A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Clinical trial NCT04279405 · COMPLETED

Trial details

NCT number: NCT04279405
Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Small Lymphocytic Lymphoma Lymphoplasmacytic Lymphoma Marginal Zone Lymphoma Mantle Cell Lymphoma Diffuse Large B Cell Lymphoma

Start date: 2020-06-15
Primary completion: 2021-09-30
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.